J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Asia Training Course" has been added to ResearchAndMarkets.com's offering.

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

UK stocks are slightly higher Thursday morning with investors digesting the latest batch of economic data, and earnings news, besides ...

The "Abbott Elementary" actor also shared words of encouragement she received from Cicely Tyson, Maya Angelou and Sidney ...

Cancer has long been one of the most feared diseases in the world. Now, a groundbreaking development in vaccine technology ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,01,355.31 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...